Another immunoinhibitory pathway of interest is IDO1, a rate-limiting oxidoreductase (Macchiarulo et al., 2009), which is currently being explored as part of combined photodynamic therapy and checkpoint blockade immunotherapy for triple-negative breast cancer (Wu et al., 2021). The gene discussed is IDO1; the disease is triple-negative breast carcinoma.